Loading...
Market
What will be Sunlenca's market share in HIV prevention drugs by end of 2024?
3
Resolution / Starting Odds
0-10% • 25%
11-20% • 25%
21-30% • 25%
31%+ • 25%
Market analysis reports from reputable sources like IMS Health
Story
Gilead's Sunlenca Shows 100% Efficacy in HIV Prevention Trial
Jun 20, 2024, 12:54 PM
Gilead Sciences announced that its twice-yearly injectable antiviral drug, lenacapavir, also known as Sunlenca, demonstrated 100% efficacy in preventing HIV infection in women during a late-stage trial. The study, which included over 2,000 women, showed that lenacapavir was more effective than the company's existing daily pill, Truvada. Researcher Joe Eron described the results as remarkable, noting that there were no infections among the participants. This trial is part of Gilead's most comprehensive and diverse HIV prevention program to date, underscoring the company's commitment to serving the needs of individuals seeking pre-exposure prophylaxis (PrEP).
View original story
Similar markets
Sunlenca surpasses Truvada • 33%
Sunlenca equals Truvada • 34%
Truvada retains lead • 33%
Below 10% • 25%
10% - 20% • 25%
20% - 30% • 25%
Above 30% • 25%
Less than 10% • 25%
10%-30% • 25%
31%-50% • 25%
More than 50% • 25%
Less than 25% • 25%
25% to 50% • 25%
50% to 75% • 25%
More than 75% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
Less than 25% • 25%
25% to 50% • 25%
50% to 75% • 25%
More than 75% • 25%
Kisunla > 50% • 25%
Kisunla 30-50% • 25%
Kisunla 10-30% • 25%
Kisunla < 10% • 25%
Less than 10 • 25%
10 to 20 • 25%
21 to 30 • 25%
More than 30 • 25%
0-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%
Below 10% • 33%
10-20% • 33%
Above 20% • 33%
Fewer than 10 countries • 25%
10 to 20 countries • 25%
21 to 30 countries • 25%
More than 30 countries • 25%